Novel oral contraceptive for heavy menstrual bleeding: Estradiol valerate and dienogest

International Journal of Women's Health

Volumn 5, Issue 1, 2013, Pages 313-321

  Rafie, Sally ^a   Borgelt, Laura ^b   Koepf, Erin R ^c   Temple Cooper, Mary E ^d   Joy Lehman, K ^e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF NEW ENGLAND   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Contraception; Dienogest; Estradiol valerate; Menorrhagia; Menstrual disorders; Natazia

Indexed keywords

DANAZOL; DIENOGEST; DIENOGEST PLUS ESTRADIOL VALERATE; ESTRADIOL; ESTRADIOL VALERATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FERRITIN; FOLLITROPIN; GESTAGEN; GONADORELIN; GONADORELIN AGONIST; GONADOTROPIN ANTAGONIST; IBUPROFEN; LEVONORGESTREL; LUTEINIZING HORMONE; MECLOFENAMIC ACID; MEDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; TRANEXAMIC ACID;

ABDOMINAL PAIN; ACNE; AMENORRHEA; ANOVULATION; AUTONOMIC NEUROPATHY; BREAST CANCER; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; FERRITIN BLOOD LEVEL; GLUCOSE METABOLISM; HEART INFARCTION; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HORMONAL THERAPY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; IRON METABOLISM; IRON THERAPY; LIPID METABOLISM; LIVER FOCAL NODULAR HYPERPLASIA; MASTALGIA; MENORRHAGIA; METRORRHAGIA; MULTIPLE CYCLE TREATMENT; OCULAR HISTOPLASMOSIS; OVARY CYST; PATIENT COMPLIANCE; PROTEIN FUNCTION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UTERUS MYOMA; VAGINITIS; WEIGHT GAIN;

EID: 84879045407     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S31922     Document Type: Review

References (44)

1. Cote I, Jacobs P, Cumming DC. Use of health services associated with increased menstrual loss in the United States. Am J Obstet Gynecol. 2003;188:343-348.
2. Spencer CP, Whitehead MI. Endometrial assessment re-visited. Br J Obstet Gynaecol. 1999;106:623-632.
3. Thompson BL, Ponce de Leon R, Kieke B, Velebil P, Wingo PA. Trends in hospitalizations for abnormal uterine bleeding in the United States: 1980-1992. J Women's Health. 1997;6:73-81.
4. Shapley M, Jordan K, Croft PR. Increased vaginal bleeding and psychological distress: a longitudinal study of their relationship in the community. BJOG. 2003;110:548-554.
5. Cote I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol. 2002;100: 683-687.
6. Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:3-13.
7. Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in abnormal uterine bleeding. Value Health. 2007;10:183-194.
8. American College of Obstetricians and Gynecologists. Practice bulletin no 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012;120:197-206.
9. Fraser IS, Critchley HO, Munro HG, Broder M. A process designed to lead to international agreement on terminologies and definitions to be used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007;87:466-476.
10. James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia. 2005;11:295-307.
11. Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG. 2004:734-740.
12. Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol. 2001;97:630-636.
13. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998;351:485-489.
14. Natazia (estradiol valerate/dienogest) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2012. Available from: http://labeling.bayerhealthcare.com/html/products/pi/natazia_pi.pdf. Accessed April 9, 2013.
15. Fruzzetti F, Bitzer J. Review of clinical experience with estradiol in combined oral contraceptives. Contraception. 2010;81:8-15.
16. Kiley JW, Shulman LP. Estradiol valerate and dienogest: a new approach to oral contraception. Int J Womens Health. 2011;3:281-286.
17. Palacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol. 2010;149:57-62.
18. Zeun S, Lu M, Uddin A, et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2009;14:221-232.
19. Ruan X, Seeger H, Mueck AO. The pharmacology of dienogest. Maturitas. 2012;71:337-344.
20. Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids. 2008;73:222-231.
21. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011;117:777-787.
22. Fraser IS, Romer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod. 2011;26:2698-2708.
23. Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomized, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16:258-269.
24. Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M. Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception. 2012;86:96-101.
25. Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven cycle, randomized, comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80: 436-444.
26. Parke S, Nahum G, Mellinger U, Junge W. Metabolic effect of a new four-phasic oral contraceptive containing estradiol valerate and dienogest. Obstet Gynecol. 2008;111 Suppl 4:S12-S13.
27. Hoy SM, Scott LJ. Estradiol valerate/dienogest: in oral contraception. Drugs. 2009;69:1635-1646.
28. Parke S, Junge W, Mellinger U, Dujkers I, Klipping C. Comparative effects of a four-phasic regimen of estradiol valerate/dienogest versus ethinyl estradiol/levonorgestrel on haemostatic parameters. Hum Reprod. 2008;23 Suppl 1:i78-i79.
29. International Active Surveillance Study-Safety of Contraceptives: Role of Estrogens (INAS-SCORE). Available from: from: http://clinicaltrials.gov/. Accessed January 31, 2013.
30. Nelson A, Sampson-Landers C, Parke S, Jensen JT. Efficacy of estradiol valerate/dienogest OC: results of 3 large studies in North America and Europe. Abstract presented at the 57th Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists, May 2-6, 2009, Chicago, IL.
31. Borgelt LM, Martell CW. Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Ther. 2012;34:37-55.
32. American College of Obstetricians and Gynecologists. ACOG practice bulletin: management of anovulatory bleeding. Int J Gynaecol Obstet. 2001;72:263-271.
33. [No authors listed]. ACOG practice bulletin: Noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010;110:206-218.
34. Shaaban MM, Zakherah MS, El-Nashar SA, et al. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011;83:48-54.
35. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med. 2013;368:128-137.
36. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005;19:CD002126.
37. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991;31:66-70.
38. Mäkäräinen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol. 1986;93:974-978.
39. Hall P, Maclachlan N, Thorn N, Nudd MW, Taylor CG, Garrioch DB. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol. 1987;94:554-558.
40. Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2002;1: CD000400.
41. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 1993;76:1217-1223.
42. Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998;70:432-439.
43. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010. MMWR. Available from: http://www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf. Accessed April 9, 2013.
44. World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 4th ed. Geneva, Switzerland: World Health Organization; 2009. Available from: http://www.who.int/reproductivehealth/publications/family_planning/9789241563888/en/index.html. Accessed April 9, 2013.